This study collects and studies tissue and blood samples from patients with prostate or bladder/urothelial cancer that has recurred (come back) at or near the same place as the original (primary) tumor or has spread to other parts of the body. Studying samples of blood and tissue samples from patients with prostate or bladder/urothelial cancer in the laboratory may help doctors learn more about new biomarkers, potential drug targets, and resistance developing in response to treatment. It may also help doctors find better ways to treat the cancer.
Eligibility criteria
This trial accepts healthy volunteers
Qualifiers
Patients with localized and/or metastatic bladder/urothelial or prostate cancer who have disease in the primary organ, biopsy accessible bone metastases (collaborating radiologists will determine if bone metastasis is appropriate for biopsy) or soft tissue metastases are eligible; men and women without cancer are eligible to have blood or normal tissue collected if acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder); in patients without malignancy, no additional tissue beyond that necessary for care will be procured
Ability to adequately understand and give informed consent
Local or metastatic disease to soft tissue or bone at sites accessible to biopsy with minimal risk of complications Or the ability to obtain tissue with minimal risk of complication from a surgical procedure being conducted as a part of another research study Or for standard of care purposes or patients who have archival tissue collected for research or standard of care who are willing to donate archival tissue for this study
Alternatively, men and women without cancer or who are at risk of developing cancer are eligible to have blood or normal tissue collected if acquired; tissue will only be acquired as part of non-research procedures (e.g. transurethral resection of the prostate or bladder; in patients without malignancy, no additional tissue beyond that necessary for care will be procured
Disqualifiers
Patients unable to stop chronic anticoagulation with warfarin or Lovenox for less than 3 days
Serious or uncontrolled infection
Treatment with a vascular endothelial growth factor (VEGF) inhibitor (such as Avastin) within the past 28 days
Trial population
Patients with prostate or bladder/urothelial cancer treated in genitourinary oncology practices at University of Washington Medical Center, Seattle Cancer care Alliance and Harborview Medical Center and healthy controls
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Cytology Specimen Collection Procedure
Other intervention
Correlative studies
Laboratory Biomarker Analysis
Other intervention
Correlative studies
Treatment groups
1,500 Participants
are divided into 1 treatment group
Group A: Ancillary-correlative (blood and tissue collection)2 interventions
Trial outcomes
Primary outcomes
1
DNA genomic sequencing
Time frame
Up to 6 years
2
Gene expression profile using microarray assays
Time frame
Up to 6 years
3
Mutation mapping using the OncoMap and other genotyping techniques
Time frame
Up to 6 years
Secondary outcomes
1
Expression of androgen metabolic enzymes by quantitative real time-polymerase chain reaction
Time frame
Up to 6 years
2
Proteomic profile
Time frame
Up to 6 years
Other outcomes
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
